{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-389829","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-09-14T11:06:27+00:00","discovered_at":"2026-09-14T11:10:02.591331+00:00","generated_at":"2026-09-14T11:10:13.006461+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Corbus CANYON-1: CRB-913 hits 5% mean weight loss at 60 mg; all doses p<0.0001","bullets":["Phase 1b CANYON-1 (NCT07310901): 254 obese adults, 16-week trial; LS mean weight loss vs placebo: 2.8% (20 mg), 3.3% (40 mg), 5.0% (60 mg) at week 12, all p<0.0001.","Safety: no serious psychiatric AEs, no suicidality; GI AEs milder than oral GLP-1s (vomiting 1.6-8.2% vs 31% for semaglutide 25 mg).","Discontinuation rate due to AEs 3.1%-13.1%, markedly lower than monlunabant's 13%-42%.","Data selected for late-breaking presentation at ObesityWeek 2026 (Nov 14-17, 2026).","Plans FDA engagement and Phase 2 monotherapy start in 1H 2027; evaluating combo with GLP-1 therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-389829","json":"https://secwatch.observer/filing/0001193125-26-389829.json","markdown":"https://secwatch.observer/filing/0001193125-26-389829.md","text":"https://secwatch.observer/filing/0001193125-26-389829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/0001193125-26-389829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526389829/crbp-20260914.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T11:10:13.006461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}